The company has revised upward its earnings guidance for the interim period of the fiscal year ending May 2027. Interim net sales are 3,500 hundred million yen, operating income 250 hundred million yen, ordinary income 240 hundred million yen, interim net income 160 hundred million yen, and interim net income per share is 39.75 yen. Compared with the previous guidance, net sales are +200 hundred million yen, operating income +100 hundred million yen, ordinary income +120 hundred million yen, and interim net income +70 hundred million yen. Compared with the same period of the previous fiscal year, net sales were 3,681 hundred million yen, operating income 349 hundred million yen, ordinary income 336 hundred million yen, and interim net income 224 hundred million yen. Full-year guidance remains unchanged. Reasons for the revision include strong performance in pharmaceutical active ingredient sales, partial pull-forward of sales in core chemical products, and robust sales of high-value-added products in the semiconductor-related market.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4885","jir_company_name":"Muromachi Chemicals Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-15","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4885-20261015-02.pdf","jir_short_summary":"The company has revised upward its earnings guidance for the interim period of the fiscal year ending May 2027. Interim net sales are 3,500 hundred million yen, operating income 250 hundred million yen, ordinary income 240 hundred million yen, interim net income 160 hundred million yen, and interim net income per share is 39.75 yen. Compared with the previous guidance, net sales are +200 hundred million yen, operating income +100 hundred million yen, ordinary income +120 hundred million yen, and interim net income +70 hundred million yen. Compared with the same period of the previous fiscal year, net sales were 3,681 hundred million yen, operating income 349 hundred million yen, ordinary income 336 hundred million yen, and interim net income 224 hundred million yen. Full-year guidance remains unchanged. Reasons for the revision include strong performance in pharmaceutical active ingredient sales, partial pull-forward of sales in core chemical products, and robust sales of high-value-added products in the semiconductor-related market.","jir_summary":"### Details of the Revision to Earnings Guidance\nBy resolution of the Board of Directors announced today, the Company has revised upward its earnings guidance for the interim period of the fiscal year ending May 2027. Interim net sales are 3,500 hundred million yen, operating income is 250 hundred million yen, ordinary income is 240 hundred million yen, and interim net income is 160 hundred million yen, with interim net income per share of 39.75 yen. Compared with the previously announced guidance, net sales increased by 6.1%, operating income by 66.7%, ordinary income by 100.0%, and interim net income by 77.8%. The full-year guidance remains unchanged at this time.\n\n### Background and Points to Note Regarding the Revision\nFactors behind the revision include higher-than-expected sales of imported active pharmaceutical ingredients in the pharmaceutical business, partial pull-forward of sales of the core ion-exchange resin product in the chemicals business, strong sales of high-value-added products driven by renewed activity in the semiconductor-related market, and temporary demand capture. The full-year earnings guidance is unchanged for now, and may be revised depending on future developments.","jir_financial_highlights":"Net Sales: 3,500 (From previous guidance 3,300 -> +6.1%)\nOperating Income: 250 (From previous guidance 150 -> +66.7%)\nOrdinary Income: 240 (From previous guidance 120 -> +100.0%)\nInterim Net Income: 160 (From previous guidance 90 -> +77.8%)\nInterim Net Income per Share: 39.75 (\uff0d)","jir_category":"","jir_hashtags":"#MuromachiChemicals, #RevisionToEarningsGuidance","jir_key_figures":"Net Sales: 3,500 hundred million yen\nOperating Income: 250 hundred million yen\nOrdinary Income: 240 hundred million yen\nInterim Net Income: 160 hundred million yen\nInterim Net Income per Share: 39.75 yen","jir_meta_title":"Muromachi Chemicals Inc. Revises Earnings Guidance | Interim Net Sales 3,500 hundred million yen, Profits Upwardly Revised","jir_meta_description":"Muromachi Chemicals Inc. has revised upward its earnings guidance for the interim period of the fiscal year ending May 2027. Interim net sales 3,500 hundred million yen, operating income 250 hundred million yen, ordinary income 240 hundred million yen, interim net income 160 hundred million yen. Summarizes growth drivers versus the prior year and the decision to keep full-year guidance unchanged.","jir_og_title":"Muromachi Chemicals Inc. Revises Earnings Guidance | Interim Net Sales 3,500 hundred million yen","jir_og_description":"Muromachi Chemicals Inc. has revised upward its interim earnings guidance: net sales 3,500 hundred million yen, operating income 250 hundred million yen, ordinary income 240 hundred million yen, interim net income 160 hundred million yen. Full-year guidance remains unchanged.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":60599,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"earnings_guidance","footnotes":""},"sector":[],"importance":[],"class_list":["post-131901","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n